PIONEER 6 results show reduced MACE with oral semaglutide in type 2 diabetes patients with high CV risk
Results from the PIONEER 6 trial suggest that oral semaglutide is safe for patients with type 2 diabetes at high cardiovascular (CV) risk. PIONEER researchers, including Mansoor Husain, MD, and John B. Buse, MD, PhD, reported that oral semaglutide, the first GLP-1 receptor agonist for oral administration, reduced CV death and all-cause mortality by nearly 50 percent versus placebo after a median follow-up of 15.9 months. Read more